Prostate Cancer Cells Increase Androgen Sensitivity by Increase in Nuclear Androgen Receptor and Androgen Receptor Coactivators; A Possible Mechanism of Hormone-Resistance of Prostate Cancer Cells

REFERENCES

• Petrylak D. P., Tangen C. M., Hussain M. H. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 513–1520
   Google Scholar
• Tannock I. F., de Wit R., Berry W. R. TAX 327 Investigators. docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• Harada S., Keller E. T., Fujimoto N. Long-term exposure of tumor necrosis factor α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 2001; 46: 319–326
   PubMed Web of Science ®Google Scholar
• Fujimoto N., Mizokami A., Harada S., Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001; 58: 289–294
   PubMedGoogle Scholar
• Mizokami A., Saiga H., Matsui T., Mita T., Sugita A. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol. Jpn. 1992; 39: 235–243
   PubMedGoogle Scholar
• Miyamoto H., Marwah P., Marwah A., Lardy H., Chang C. 3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc. Natl. Acad. Sci. USA 2003; 100: 4440–4444
   PubMed Web of Science ®Google Scholar
• Chang C., Kokontis J., Liao S. Structual analysis of complementary DNA and amino acid sequences of the human and rat androgen receptors. Proc. Natl. Acad. Sci. USA 1998; 85: 7211–7215
   Google Scholar
• Jester G., Trapman J., Brinkmann A. O. Nuclear import of the androgen receptor. Biochem. J. 1993; 293: 761–768
   PubMed Web of Science ®Google Scholar
• Zhou Z.-X., Sar M., Simenral J. A., Lane M. V., Wilson E. M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. J. Biol. Chem. 1994; 269: 13115–13123
   PubMed Web of Science ®Google Scholar
• So A., Gleave M., Hurtado-Col A., Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 2005; 23: 1–9
   PubMed Web of Science ®Google Scholar
• Edwards J., Krishna N. S., Grigor K. M., Bartlett L. M.S. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer. 2003; 89: 552–556
   PubMed Web of Science ®Google Scholar
• Chen C. D., Welsbier D. S., Tran C. Molecular determinations of resistance to antiandrogen therapy. Nat. Med. 2004; 10: 33–39
   PubMed Web of Science ®Google Scholar
• Gregory C. W., Johnson R. T., Mohler J. L., French F. S., Wilson E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001; 61: 2892–2898
   PubMed Web of Science ®Google Scholar
• Hu Y. C., Yeh S., Yeh S. D. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 2004; 279: 33438–33446
   PubMed Web of Science ®Google Scholar
• Buchanan G., Yang M., Harris J. M. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinology 2001; 15: 46–56
   PubMed Web of Science ®Google Scholar
• Shibata H., Spencer T. E., Onate S. A. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent. Prog. Horm. Res. 1997; 52: 141–165
   PubMedGoogle Scholar
• Fujimoto N., Yeh S., Kang H. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 1999; 274: 8316–8321
   PubMed Web of Science ®Google Scholar
• Kang H., Yeh S., Fujimoto N., Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with androgen receptor. J. Biol. Chem. 1999; 274: 8570–8576
   PubMed Web of Science ®Google Scholar
• Bevan C. L., Hoare S., Claessens F., Heery D. M., Parker M. G. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell. Biol. 1999; 19: 8383–8392
   PubMed Web of Science ®Google Scholar
• Voegel J. J., Heine M. J.S., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996; 15: 3667–3675
   PubMed Web of Science ®Google Scholar
• Yeh S., Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. USA 1996; 93: 5517–5521
   PubMed Web of Science ®Google Scholar
• Li H., Gomes P. J., Chen J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 1997; 94: 8479–8484
   PubMed Web of Science ®Google Scholar
• Muller J. N., Isele U., Metzger E. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 2000; 19: 359–369
   PubMed Web of Science ®Google Scholar
• Agoulnik I. U., Krause W. C., Bingman W. E., 3rd. Repressors of androgen and progesterone receptor action. J. Biol. Chem. 2003; 278: 31136–31148
   PubMed Web of Science ®Google Scholar
• Linja M. J., Porkka K. P., Kang Z. Expression of androgen receptor coregulators in prostate caner. Clin. Cancer Res. 2004; 10: 1032–1040
   PubMed Web of Science ®Google Scholar
• Gregory C. W., He B., Johnson R. T. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61: 4315–4319
   PubMed Web of Science ®Google Scholar
• Nishimura K., Ting H. J., Harada Y. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res. 2003; 63: 4888–4894
   PubMed Web of Science ®Google Scholar
• Gregory C. W., Hamil K. G., Kin D. Androgen receptor expression in androgen independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 1998; 58: 5718–5724
   PubMed Web of Science ®Google Scholar
• Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 2004; 90: 2312–2316
   PubMed Web of Science ®Google Scholar